Search results
ACC.24: The TACTiC Trial
Added:
1 week ago
Video
ESC 23: LODESTAR Trial
Added:
7 months ago
Video
Added:
3 years ago
The majority of all heart attacks and strokes are observed in individuals without elevated cholesterol levels, and some are in those with low cholesterol. Risk factors are absent in approximately 20% of patients with vascular events. If traditional risk factors seem to be unreliable for predicting events in a large number of individuals, expanding the classic risk prediction model would be the…
View more
Added:
3 years ago
Background and aims: The aim of the study was to investigate the influence of combined lipid lowering therapy with rosuvastatin and ezetimibe on lipid profile, inflammatory state and pro-inflammatory cytokines in dyslipidaemic patients with coronary heart disease (CHD) and metabolic syndrome (MS).
Material and methods: 128 patients with CHD and MS were randomly divided into two groups of 64. The…
View more
Added:
3 years ago
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide.1 The relationship between coronary heart disease (CHD) and elevated low-density lipoprotein cholesterol (LDL-C) levels is well established.2 Several large-scale trials, in both primary and secondary prevention settings, have shown that lowering LDL-C levels using statins substantially reduces cardiovascular…
View more
Added:
3 years ago
Statins are currently the most efficacious and widely prescribed lipid-lowering medications.1 Numerous randomised controlled trials across a spectrum of baseline atherosclerotic cardiovascular disease (ASCVD) risk show that a 1.0 mmol/L (~40 mg/dL) reduction in low-density lipoprotein cholesterol (LDL-C) with statin therapy is associated with an overall 21 % reduction in major vascular events and…
View more
Added:
3 years ago
The strong positive correlation between plasma low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) mortality has been documented beyond any doubt.1 A large body of trials aiming at reducing elevated LDL-C levels also shows that therapeutic intervention results in a proportional reduction of CV events independent of the type of intervention (i.e. diet versus drugs or…
View more
Added:
3 years ago
Premise
Evidence spanning from the pathogenesis of atherosclerosis to epidemiological studies consistently support the direct association of elevated plasma low-density lipoprotein-cholesterol (LDL-C) with the increased risk of cardiovascular disease (CVD). Meta-analysis of 14 trials of statin therapy, with more than 90,000 participants, has shown that each 1mmol/l (39mg/dl) of LDL-C reduction…
View more
Added:
1 year ago
ACC.23/WCC — Principle investigator of YELLOW III, Dr Annapoorna Subhash Kini(Mount Sinai Hospital, US) joins us to talk about the study that assessed the effect of evolocumab (Repatha) on coronary plaque morphology using intravascular imaging and gene expression analysis of peripheral blood mononuclear cells (PBMC) in 140 patients with stable CAD on maximally tolerated statin therapy …
View more
Added:
3 years ago
Statins are most frequently prescribed for the primary prevention of cardiovascular disease due to their lipid-lowering properties. They are known to exert their effect by competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The reduction in the synthesis of cholesterol induces upregulation of LDL receptors in the liver, resulting in increased clearance and…
View more
